<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(4)</volume><submitter>Mostaghimi A</submitter><funding>Pfizer</funding><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Comparative data on the economic burden of alopecia areata relative to the general population are limited. The objective of this retrospective database analysis was to evaluate healthcare resource utilization and direct medical costs among patients with alopecia areata from the US payer perspective compared with matched controls.&lt;h4>Methods&lt;/h4>Validated billing codes were used to identify patients with alopecia areata from the IQVIA PharMetrics Plus (2016-2018) who had continuous pharmacy and medical enrollment for 365 days both before (baseline period) and after (evaluation period) the index date. Demographic and clinical characteristics were characterized, and baseline comorbidities were assessed with the Quan Charlson Comorbidity Index.&lt;h4>Results&lt;/h4>Using the exa</pubmed_abstract><journal>Dermatology and therapy</journal><pagination>1027-1040</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9021349</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA.</pubmed_title><pmcid>PMC9021349</pmcid><pubmed_authors>Gruben D</pubmed_authors><pubmed_authors>Meche A</pubmed_authors><pubmed_authors>Sikirica V</pubmed_authors><pubmed_authors>Smith TW</pubmed_authors><pubmed_authors>Mostaghimi A</pubmed_authors><pubmed_authors>Xenakis J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA.</name><description>&lt;h4>Introduction&lt;/h4>Comparative data on the economic burden of alopecia areata relative to the general population are limited. The objective of this retrospective database analysis was to evaluate healthcare resource utilization and direct medical costs among patients with alopecia areata from the US payer perspective compared with matched controls.&lt;h4>Methods&lt;/h4>Validated billing codes were used to identify patients with alopecia areata from the IQVIA PharMetrics Plus (2016-2018) who had continuous pharmacy and medical enrollment for 365 days both before (baseline period) and after (evaluation period) the index date. Demographic and clinical characteristics were characterized, and baseline comorbidities were assessed with the Quan Charlson Comorbidity Index.&lt;h4>Results&lt;/h4>Using the exa</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-19T12:54:36.691Z</modification><creation>2025-04-19T12:54:36.691Z</creation></dates><accession>S-EPMC9021349</accession><cross_references><pubmed>35381975</pubmed><doi>10.1007/s13555-022-00710-4</doi></cross_references></HashMap>